Colleen Kusy
Stock Analyst at Baird
(0.96)
# 3,751
Out of 4,944 analysts
48
Total ratings
28.57%
Success rate
-13.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $47 → $50 | $26.58 | +88.11% | 12 | Jul 18, 2025 | |
| NUVL Nuvalent | Maintains: Outperform | $105 → $112 | $78.24 | +43.15% | 2 | Jun 25, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Outperform | $40 → $52 | $19.99 | +160.20% | 3 | Jun 16, 2025 | |
| AGEN Agenus | Maintains: Neutral | $4 → $6 | $4.54 | +32.16% | 4 | Jun 4, 2025 | |
| OCS Oculis Holding AG | Maintains: Outperform | $37 → $41 | $18.05 | +127.15% | 4 | Mar 13, 2025 | |
| CHRS Coherus Oncology | Maintains: Outperform | $4 → $6 | $1.00 | +500.60% | 5 | Dec 5, 2024 | |
| SYRE Spyre Therapeutics | Maintains: Outperform | $50 → $65 | $17.40 | +273.56% | 2 | Nov 13, 2024 | |
| MRSN Mersana Therapeutics | Maintains: Neutral | $100 → $75 | $6.81 | +1,001.32% | 4 | Aug 14, 2024 | |
| OCUL Ocular Therapeutix | Maintains: Outperform | $18 → $17 | $12.50 | +36.00% | 4 | Aug 8, 2024 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Outperform | $27 → $25 | $9.83 | +154.32% | 1 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $255 → $210 | $4.45 | +4,619.10% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $2.45 | +1,287.76% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $230 | $2.15 | +10,597.67% | 1 | Nov 2, 2021 |
Apellis Pharmaceuticals
Jul 18, 2025
Maintains: Outperform
Price Target: $47 → $50
Current: $26.58
Upside: +88.11%
Nuvalent
Jun 25, 2025
Maintains: Outperform
Price Target: $105 → $112
Current: $78.24
Upside: +43.15%
Enliven Therapeutics
Jun 16, 2025
Maintains: Outperform
Price Target: $40 → $52
Current: $19.99
Upside: +160.20%
Agenus
Jun 4, 2025
Maintains: Neutral
Price Target: $4 → $6
Current: $4.54
Upside: +32.16%
Oculis Holding AG
Mar 13, 2025
Maintains: Outperform
Price Target: $37 → $41
Current: $18.05
Upside: +127.15%
Coherus Oncology
Dec 5, 2024
Maintains: Outperform
Price Target: $4 → $6
Current: $1.00
Upside: +500.60%
Spyre Therapeutics
Nov 13, 2024
Maintains: Outperform
Price Target: $50 → $65
Current: $17.40
Upside: +273.56%
Mersana Therapeutics
Aug 14, 2024
Maintains: Neutral
Price Target: $100 → $75
Current: $6.81
Upside: +1,001.32%
Ocular Therapeutix
Aug 8, 2024
Maintains: Outperform
Price Target: $18 → $17
Current: $12.50
Upside: +36.00%
ORIC Pharmaceuticals
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $9.83
Upside: +154.32%
Aug 5, 2022
Maintains: Outperform
Price Target: $255 → $210
Current: $4.45
Upside: +4,619.10%
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $2.45
Upside: +1,287.76%
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $2.15
Upside: +10,597.67%